Drugs Made In America Acquisition II Corp Unit
DMIIU
30 hedge funds and large institutions have $116M invested in Drugs Made In America Acquisition II Corp Unit in 2025 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 52 closing their positions.
22.64% more ownership
Funds ownership: 0% → 22.64% (+23%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
60% less funds holding
Funds holding: 75 → 30 (-45)
75% less capital invested
Capital invested by funds: $456M → $116M (-$340M)
85% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
+$3.03M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$936K |
| 3 |
PCM
Prelude Capital Management
New York
|
+$500K |
| 4 |
HF
HRT Financial
New York
|
+$366K |
| 5 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$326K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$26.9M |
| 2 |
GCL
Glazer Capital LLC
New York
|
-$23.4M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$19.6M |
| 4 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
-$18.7M |
| 5 |
Millennium Management
New York
|
-$15M |
DMIIU Hedge Fund Activity: Q4 2025 in Review
30 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition II Corp Unit (DMIIU) for Q4 2025, worth a combined $116M — down 75% from $456M a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of DMIIU and 8 opened new positions — a net loss of 44 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Westchester Capital Management (New York), adding an estimated $3.03M. The largest seller was Magnetar Financial, exiting entirely with an estimated $26.9M sold.
- 30 institutional investors held Drugs Made In America Acquisition II Corp Unit (DMIIU) as of Q4 2025, down from 75 in Q3 2025.
- Funds reported $116M of Drugs Made In America Acquisition II Corp Unit stock for Q4 2025, down 75% quarter-over-quarter.
- 8 funds opened new Drugs Made In America Acquisition II Corp Unit positions in Q4 2025 and 52 closed out, a net change of -44 holders.
- The largest Drugs Made In America Acquisition II Corp Unit buyer in Q4 2025 was Westchester Capital Management (New York), an estimated $3.03M added.
- The largest Drugs Made In America Acquisition II Corp Unit seller in Q4 2025 was Magnetar Financial, an estimated $26.9M sold.
Based on aggregated 13F filings for Q4 2025.